PortViewPortView
Boston Scientific logo

Boston Scientific (BSX) Stock Analysis

NYSEHealth CareMedical Devices

$49.22+2.36%
1-year price historyRange $42.63 – $108.14
52-week range$49.22
$42.20$109.50

What Boston Scientific does

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Key metrics

Market cap
$73.16B
P/E (TTM)
15.88
EPS (TTM)
$3.10
Beta
0.57
Dividend yield
0.00%
Revenue / share
$14.21
50-day avg
$46.71
200-day avg
$67.59
52-week high
$109.50
52-week low
$42.20
CEO
Michael F. Mahoney

ETFs linked to BSX

Broad-market and Health Care sector ETFs an investor holding Boston Scientific is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BSX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze BSX in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Boston Scientific?
Boston Scientific trades under the ticker BSX on NYSE.
Which exchange is BSX listed on?
BSX is listed on NYSE.
What sector does Boston Scientific operate in?
Boston Scientific is classified in the Health Care sector (Medical Devices industry).
How can PortView help analyze BSX in a portfolio?
PortView shows BSX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.